Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 60 entries
Sorted by: Best Match Show Resources per page
Clinical utility of ramucirumab in advanced gastric cancer.

Biologics : targets & therapy

Chan MM, Sjoquist KM, Zalcberg JR.
PMID: 26451083
Biologics. 2015 Sep 22;9:93-105. doi: 10.2147/BTT.S62777. eCollection 2015.

Gastric cancer is currently the third most common cause of cancer deaths worldwide. Prognosis remains poor with most patients presenting with advanced or metastatic disease. A better understanding of angiogenesis has led to the investigation of drugs that inhibit...

Cite
Chan MM, Sjoquist KM, Zalcberg JR. Clinical utility of ramucirumab in advanced gastric cancer. Biologics. 2015;9:93-105doi: 10.2147/BTT.S62777.
Chan, M. M., Sjoquist, K. M., & Zalcberg, J. R. (2015). Clinical utility of ramucirumab in advanced gastric cancer. Biologics : targets & therapy, 993-105. https://doi.org/10.2147/BTT.S62777
Chan, Matthew Mk, et al. "Clinical utility of ramucirumab in advanced gastric cancer." Biologics : targets & therapy vol. 9 (2015): 93-105. doi: https://doi.org/10.2147/BTT.S62777
Chan MM, Sjoquist KM, Zalcberg JR. Clinical utility of ramucirumab in advanced gastric cancer. Biologics. 2015 Sep 22;9:93-105. doi: 10.2147/BTT.S62777. eCollection 2015. PMID: 26451083; PMCID: PMC4589126.
Copy Download .nbib Format: NLM
BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival.

Cancer investigation

Pagnano KB, Bendit I, Boquimpani C, De Souza CA, Miranda EC, Zalcberg I, Larripa I, Nardinelli L, Silveira RA, Fogliatto L, Spector N, Funke V, Pasquini R, Hungria V, Sérgio Chiattone C, Clementino N, Conchon M, Moiraghi EB, Lopez JL, Pavlovsky C, Pavlovsky MA, Cervera EE, Meillon LA, Simões B, Hamerschlak N, Bozzano AH, Mayta E, Cortes J, Bengió 5 On Behalf Of Latin American Leukemia Net Lalnet RM.
PMID: 26279306
Cancer Invest. 2015 Aug 17; Epub 2015 Aug 17.

This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS)...

Cite
Pagnano KB, Bendit I, Boquimpani C, et al. BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival. Cancer Invest. 2015;
Pagnano, K. B., Bendit, I., Boquimpani, C., De Souza, C. A., Miranda, E. C., Zalcberg, I., Larripa, I., Nardinelli, L., Silveira, R. A., Fogliatto, L., Spector, N., Funke, V., Pasquini, R., Hungria, V., Sérgio Chiattone, C., Clementino, N., Conchon, M., Moiraghi, E. B., Lopez, J. L., Pavlovsky, C., Pavlovsky, M. A., Cervera, E. E., Meillon, L. A., Simões, B., Hamerschlak, N., Bozzano, A. H., Mayta, E., Cortes, J., & Bengió 5 On Behalf Of Latin American Leukemia Net Lalnet, R. M. (2015). BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival. Cancer investigation, .
Pagnano, Katia Borgia Barbosa, et al. "BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival." Cancer investigation vol. (2015).
Pagnano KB, Bendit I, Boquimpani C, De Souza CA, Miranda EC, Zalcberg I, Larripa I, Nardinelli L, Silveira RA, Fogliatto L, Spector N, Funke V, Pasquini R, Hungria V, Sérgio Chiattone C, Clementino N, Conchon M, Moiraghi EB, Lopez JL, Pavlovsky C, Pavlovsky MA, Cervera EE, Meillon LA, Simões B, Hamerschlak N, Bozzano AH, Mayta E, Cortes J, Bengió 5 On Behalf Of Latin American Leukemia Net Lalnet RM. BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival. Cancer Invest. 2015 Aug 17; Epub 2015 Aug 17. PMID: 26279306.
Copy Download .nbib Format: NLM
Reducing clinical trial monitoring resource allocation and costs through remote access to electronic medical records.

Journal of oncology practice

Uren SC, Kirkman MB, Dalton BS, Zalcberg JR.
PMID: 23633977
J Oncol Pract. 2013 Jan;9(1):e13-6. doi: 10.1200/JOP.2012.000666.

PURPOSE: With electronic medical records (eMRs), the option now exists for clinical trial monitors to perform source data verification (SDV) remotely. We report on a feasibility study of remote access to eMRs for SDV and the potential advantages of...

Cite
Uren SC, Kirkman MB, Dalton BS, et al. Reducing clinical trial monitoring resource allocation and costs through remote access to electronic medical records. J Oncol Pract. 2013;9(1):e13-6doi: 10.1200/JOP.2012.000666.
Uren, S. C., Kirkman, M. B., Dalton, B. S., & Zalcberg, J. R. (2013). Reducing clinical trial monitoring resource allocation and costs through remote access to electronic medical records. Journal of oncology practice, 9(1), e13-6. https://doi.org/10.1200/JOP.2012.000666
Uren, Shannon C, et al. "Reducing clinical trial monitoring resource allocation and costs through remote access to electronic medical records." Journal of oncology practice vol. 9,1 (2013): e13-6. doi: https://doi.org/10.1200/JOP.2012.000666
Uren SC, Kirkman MB, Dalton BS, Zalcberg JR. Reducing clinical trial monitoring resource allocation and costs through remote access to electronic medical records. J Oncol Pract. 2013 Jan;9(1):e13-6. doi: 10.1200/JOP.2012.000666. PMID: 23633977; PMCID: PMC3545670.
Copy Download .nbib Format: NLM
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis.

Therapeutic advances in medical oncology

Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, Hurwitz H, Punt C, Diaz Rubio E, Koopman M, Cremolini C, Heinemann V, Tournigard C, Bokemeyer C, Fuchs C, Tebbutt N, Souglakos J, Doulliard JY, Kabbinavar F, Chibaudel B, de Gramont A, Shi Q, Grothey A, Adams R.
PMID: 34262614
Ther Adv Med Oncol. 2021 Jun 30;13:17588359211020547. doi: 10.1177/17588359211020547. eCollection 2021.

BACKGROUND: Benchmarking international cancer survival differences is necessary to evaluate and improve healthcare systems. Our aim was to assess the potential regional differences in outcomes among patients with metastatic colorectal cancer (mCRC) participating in international randomized clinical trials (RCTs).DESIGN:...

Cite
Yin J, Dawood S, Cohen R, et al. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Ther Adv Med Oncol. 2021;13:17588359211020547doi: 10.1177/17588359211020547.
Yin, J., Dawood, S., Cohen, R., Meyers, J., Zalcberg, J., Yoshino, T., Seymour, M., Maughan, T., Saltz, L., Van Cutsem, E., Venook, A., Schmoll, H. J., Goldberg, R., Hoff, P., Hecht, J. R., Hurwitz, H., Punt, C., Diaz Rubio, E., Koopman, M., Cremolini, C., Heinemann, V., Tournigard, C., Bokemeyer, C., Fuchs, C., Tebbutt, N., Souglakos, J., Doulliard, J. Y., Kabbinavar, F., Chibaudel, B., de Gramont, A., Shi, Q., Grothey, A., & Adams, R. (2021). Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic advances in medical oncology, 1317588359211020547. https://doi.org/10.1177/17588359211020547
Yin, Jun, et al. "Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis." Therapeutic advances in medical oncology vol. 13 (2021): 17588359211020547. doi: https://doi.org/10.1177/17588359211020547
Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, Hurwitz H, Punt C, Diaz Rubio E, Koopman M, Cremolini C, Heinemann V, Tournigard C, Bokemeyer C, Fuchs C, Tebbutt N, Souglakos J, Doulliard JY, Kabbinavar F, Chibaudel B, de Gramont A, Shi Q, Grothey A, Adams R. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Ther Adv Med Oncol. 2021 Jun 30;13:17588359211020547. doi: 10.1177/17588359211020547. eCollection 2021. PMID: 34262614; PMCID: PMC8252342.
Copy Download .nbib Format: NLM
A comparison of outcomes and survival between Victoria and Denmark in lung cancer surgery: opportunities for international benchmarking.

ANZ journal of surgery

Stenger M, Jakobsen E, Wright G, Zalcberg J, Stirling RG.
PMID: 34676962
ANZ J Surg. 2021 Oct 22; doi: 10.1111/ans.17302. Epub 2021 Oct 22.

BACKGROUNDS: Victoria (Australia) and Denmark have comparable population sizes and high-quality healthcare systems. Lung cancer surgery, however, is performed in more than 20 Victorian hospitals compared to four in Denmark. Such differences in centralization may influence outcomes. We engaged...

Cite
Stenger M, Jakobsen E, Wright G, et al. A comparison of outcomes and survival between Victoria and Denmark in lung cancer surgery: opportunities for international benchmarking. ANZ J Surg. 2021;doi: 10.1111/ans.17302.
Stenger, M., Jakobsen, E., Wright, G., Zalcberg, J., & Stirling, R. G. (2021). A comparison of outcomes and survival between Victoria and Denmark in lung cancer surgery: opportunities for international benchmarking. ANZ journal of surgery, . https://doi.org/10.1111/ans.17302
Stenger, Michael, et al. "A comparison of outcomes and survival between Victoria and Denmark in lung cancer surgery: opportunities for international benchmarking." ANZ journal of surgery vol. (2021). doi: https://doi.org/10.1111/ans.17302
Stenger M, Jakobsen E, Wright G, Zalcberg J, Stirling RG. A comparison of outcomes and survival between Victoria and Denmark in lung cancer surgery: opportunities for international benchmarking. ANZ J Surg. 2021 Oct 22; doi: 10.1111/ans.17302. Epub 2021 Oct 22. PMID: 34676962.
Copy Download .nbib Format: NLM
Factors involved in treatment decision making for women diagnosed with ductal carcinoma in situ: A qualitative study.

Breast (Edinburgh, Scotland)

Hatton A, Heriot N, Zalcberg J, Ayton D, Evans J, Roder D, Chua BH, Hersch J, Lippey J, Fox J, Saunders C, Mann GB, Synnot J, Bell RJ.
PMID: 34624754
Breast. 2021 Oct 01;60:123-130. doi: 10.1016/j.breast.2021.09.007. Epub 2021 Oct 01.

Whilst some of the diversity in management of women with ductal carcinoma in situ (DCIS) may be explained by tumour characteristics, the role of patient preference and the factors underlying those preferences have been less frequently examined. We have...

Cite
Hatton A, Heriot N, Zalcberg J, et al. Factors involved in treatment decision making for women diagnosed with ductal carcinoma in situ: A qualitative study. Breast. 2021;60:123-130doi: 10.1016/j.breast.2021.09.007.
Hatton, A., Heriot, N., Zalcberg, J., Ayton, D., Evans, J., Roder, D., Chua, B. H., Hersch, J., Lippey, J., Fox, J., Saunders, C., Mann, G. B., Synnot, J., & Bell, R. J. (2021). Factors involved in treatment decision making for women diagnosed with ductal carcinoma in situ: A qualitative study. Breast (Edinburgh, Scotland), 60123-130. https://doi.org/10.1016/j.breast.2021.09.007
Hatton, Amy, et al. "Factors involved in treatment decision making for women diagnosed with ductal carcinoma in situ: A qualitative study." Breast (Edinburgh, Scotland) vol. 60 (2021): 123-130. doi: https://doi.org/10.1016/j.breast.2021.09.007
Hatton A, Heriot N, Zalcberg J, Ayton D, Evans J, Roder D, Chua BH, Hersch J, Lippey J, Fox J, Saunders C, Mann GB, Synnot J, Bell RJ. Factors involved in treatment decision making for women diagnosed with ductal carcinoma in situ: A qualitative study. Breast. 2021 Oct 01;60:123-130. doi: 10.1016/j.breast.2021.09.007. Epub 2021 Oct 01. PMID: 34624754; PMCID: PMC8503564.
Copy Download .nbib Format: NLM
Making the move to a learning healthcare system: has the pandemic brought us one step closer?.

Australian health review : a publication of the Australian Hospital Association

Symons T, Zalcberg J, Morris J.
PMID: 34289930
Aust Health Rev. 2021 Jul 22; doi: 10.1071/AH21076. Epub 2021 Jul 22.

The notion of a learning healthcare system (LHS) is gaining traction to advance the objectives of high-quality patient-centred care. Within such a system, real-world data analysis, clinical research and health service research are core activities of the health system....

Cite
Symons T, Zalcberg J, Morris J. Making the move to a learning healthcare system: has the pandemic brought us one step closer?. Aust Health Rev. 2021;doi: 10.1071/AH21076.
Symons, T., Zalcberg, J., & Morris, J. (2021). Making the move to a learning healthcare system: has the pandemic brought us one step closer?. Australian health review : a publication of the Australian Hospital Association, . https://doi.org/10.1071/AH21076
Symons, Tanya, et al. "Making the move to a learning healthcare system: has the pandemic brought us one step closer?." Australian health review : a publication of the Australian Hospital Association vol. (2021). doi: https://doi.org/10.1071/AH21076
Symons T, Zalcberg J, Morris J. Making the move to a learning healthcare system: has the pandemic brought us one step closer?. Aust Health Rev. 2021 Jul 22; doi: 10.1071/AH21076. Epub 2021 Jul 22. PMID: 34289930.
Copy Download .nbib Format: NLM
TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes.

Blood advances

Gurnari C, Pagliuca S, Guan Y, Adema V, Hershberger CE, Ni Y, Awada H, Kongkiatkamon S, Zawit M, Coutinho D, Zalcberg IR, Ahn JS, Kim HJ, Kim DDH, Minden MD, Jansen JH, Meggendorfer M, Haferlach C, Jha BK, Haferlach T, Maciejewski JP, Visconte V.
PMID: 34768283
Blood Adv. 2021 Nov 12; doi: 10.1182/bloodadvances.2021005418. Epub 2021 Nov 12.

Decrease in DNA dioxygease activity generated by TET2 gene family is crucial in myelodysplastic syndromes (MDS). The general down-regulation of 5-hydroxymethylcytosine (5-hmC) argues for a role of DNA demethylation in MDS beyond TET2 mutations, which albeit frequent, do not...

Cite
Gurnari C, Pagliuca S, Guan Y, et al. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Adv. 2021;doi: 10.1182/bloodadvances.2021005418.
Gurnari, C., Pagliuca, S., Guan, Y., Adema, V., Hershberger, C. E., Ni, Y., Awada, H., Kongkiatkamon, S., Zawit, M., Coutinho, D., Zalcberg, I. R., Ahn, J. S., Kim, H. J., Kim, D. D. H., Minden, M. D., Jansen, J. H., Meggendorfer, M., Haferlach, C., Jha, B. K., Haferlach, T., Maciejewski, J. P., & Visconte, V. (2021). TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood advances, . https://doi.org/10.1182/bloodadvances.2021005418
Gurnari, Carmelo, et al. "TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes." Blood advances vol. (2021). doi: https://doi.org/10.1182/bloodadvances.2021005418
Gurnari C, Pagliuca S, Guan Y, Adema V, Hershberger CE, Ni Y, Awada H, Kongkiatkamon S, Zawit M, Coutinho D, Zalcberg IR, Ahn JS, Kim HJ, Kim DDH, Minden MD, Jansen JH, Meggendorfer M, Haferlach C, Jha BK, Haferlach T, Maciejewski JP, Visconte V. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Adv. 2021 Nov 12; doi: 10.1182/bloodadvances.2021005418. Epub 2021 Nov 12. PMID: 34768283.
Copy Download .nbib Format: NLM
Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.

Therapeutic advances in medical oncology

Ferraro D, Zalcberg J.
PMID: 25342989
Ther Adv Med Oncol. 2014 Sep;6(5):222-8. doi: 10.1177/1758834014544892.

Gastrointestinal stromal tumors (GISTs) are rare malignancies, and historically had a poor prognosis, with little benefit from traditional anticancer therapies. The management of GISTs has undergone a paradigm change in recent years with the detection of activating mutations in...

Cite
Ferraro D, Zalcberg J. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy. Ther Adv Med Oncol. 2014;6(5):222-8doi: 10.1177/1758834014544892.
Ferraro, D., & Zalcberg, J. (2014). Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy. Therapeutic advances in medical oncology, 6(5), 222-8. https://doi.org/10.1177/1758834014544892
Ferraro, Danielle, and Zalcberg, John. "Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy." Therapeutic advances in medical oncology vol. 6,5 (2014): 222-8. doi: https://doi.org/10.1177/1758834014544892
Ferraro D, Zalcberg J. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy. Ther Adv Med Oncol. 2014 Sep;6(5):222-8. doi: 10.1177/1758834014544892. PMID: 25342989; PMCID: PMC4206614.
Copy Download .nbib Format: NLM
Regulation of MDR1 gene expression: emerging concepts.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Kantharidis P, El-Osta S, Silva M, Lee G, Hu XF, Zalcberg J.
PMID: 11498374
Drug Resist Updat. 2000 Apr;3(2):99-108. doi: 10.1054/drup.2000.0121.

Drug resistance genes, such as MDR1, involved in drug efflux, and their regulation have been the subject of intense research efforts in the past 10 years. Many factors and cellular signalling pathways play a role in the regulation of...

Cite
Kantharidis P, El-Osta S, Silva M, et al. Regulation of MDR1 gene expression: emerging concepts. Drug Resist Updat. 2000;3(2):99-108doi: 10.1054/drup.2000.0121.
Kantharidis, P., El-Osta, S., Silva, M., Lee, G., Hu, X. F., & Zalcberg, J. (2000). Regulation of MDR1 gene expression: emerging concepts. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 3(2), 99-108. https://doi.org/10.1054/drup.2000.0121
Kantharidis, Phillip, et al. "Regulation of MDR1 gene expression: emerging concepts." Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy vol. 3,2 (2000): 99-108. doi: https://doi.org/10.1054/drup.2000.0121
Kantharidis P, El-Osta S, Silva M, Lee G, Hu XF, Zalcberg J. Regulation of MDR1 gene expression: emerging concepts. Drug Resist Updat. 2000 Apr;3(2):99-108. doi: 10.1054/drup.2000.0121. PMID: 11498374.
Copy Download .nbib Format: NLM
RUNX1T1 is overexpressed in imatinib mesylate-resistant cells.

Molecular medicine reports

Binato R, Mencalha A, Pizzatti L, Scholl V, Zalcberg I, Abdelhay E.
PMID: 21475882
Mol Med Rep. 2009 Jul-Aug;2(4):657-61. doi: 10.3892/mmr_00000153.

The Philadelphia (Ph) chromosome, which occurs as a result of a translocation between chromosomes 9 and 22, generates a BCR-ABL fusion oncogene in leukaemia cells. The BCR-ABL fusion protein has constitutive tyrosine kinase activity. The development of imatinib mesylate...

Cite
Binato R, Mencalha A, Pizzatti L, et al. RUNX1T1 is overexpressed in imatinib mesylate-resistant cells. Mol Med Rep. 2009;2(4):657-61doi: 10.3892/mmr_00000153.
Binato, R., Mencalha, A., Pizzatti, L., Scholl, V., Zalcberg, I., & Abdelhay, E. (2009). RUNX1T1 is overexpressed in imatinib mesylate-resistant cells. Molecular medicine reports, 2(4), 657-61. https://doi.org/10.3892/mmr_00000153
Binato, Renata, et al. "RUNX1T1 is overexpressed in imatinib mesylate-resistant cells." Molecular medicine reports vol. 2,4 (2009): 657-61. doi: https://doi.org/10.3892/mmr_00000153
Binato R, Mencalha A, Pizzatti L, Scholl V, Zalcberg I, Abdelhay E. RUNX1T1 is overexpressed in imatinib mesylate-resistant cells. Mol Med Rep. 2009 Jul-Aug;2(4):657-61. doi: 10.3892/mmr_00000153. PMID: 21475882.
Copy Download .nbib Format: NLM
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous .

Clinical cancer research : an official journal of the American Association for Cancer Research

Bauer S, Heinrich MC, George S, Zalcberg JR, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Su Y, Ruiz-Soto R, Blay JY, von Mehren M, Schöffski P.
PMID: 34503977
Clin Cancer Res. 2021 Dec 01;27(23):6333-6342. doi: 10.1158/1078-0432.CCR-21-1864. Epub 2021 Sep 09.

PURPOSE: Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in PATIENTS AND METHODS: Tumor tissue and liquid biopsy samples that captured circulating tumor DNA were collected prior to study enrollment and sequenced using next-generation sequencing. Subgroups were...

Cite
Bauer S, Heinrich MC, George S, et al. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous . Clin Cancer Res. 2021;27(23):6333-6342doi: 10.1158/1078-0432.CCR-21-1864.
Bauer, S., Heinrich, M. C., George, S., Zalcberg, J. R., Serrano, C., Gelderblom, H., Jones, R. L., Attia, S., D'Amato, G., Chi, P., Reichardt, P., Meade, J., Su, Y., Ruiz-Soto, R., Blay, J. Y., von Mehren, M., & Schöffski, P. (2021). Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(23), 6333-6342. https://doi.org/10.1158/1078-0432.CCR-21-1864
Bauer, Sebastian, et al. "Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous ." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,23 (2021): 6333-6342. doi: https://doi.org/10.1158/1078-0432.CCR-21-1864
Bauer S, Heinrich MC, George S, Zalcberg JR, Serrano C, Gelderblom H, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Su Y, Ruiz-Soto R, Blay JY, von Mehren M, Schöffski P. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous . Clin Cancer Res. 2021 Dec 01;27(23):6333-6342. doi: 10.1158/1078-0432.CCR-21-1864. Epub 2021 Sep 09. PMID: 34503977.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 60 entries